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Abstract
Background: The nomograms used for prostate cancer risk assessment in Western countries are not directly
applicable to Chinese males; consequently, we have developed a new model to evaluate the risk of them
developing this disease.
Methods: A total of 1104 patients who had undergone trans-rectal ultrasound (TRUS)-guided 12 + 1-core prostate
biopsy were retrospectively evaluated in the first stage of the study. Age, prostate-specific antigen (PSA), the free/
total PSA ratio (f/t), digital rectal examination (DRE) findings, the presence of a hypoechoic mass revealed using
ultrasound, ultrasonic detection of microcalcifications, prostate volume (PV) and PSA density were considered
as predictive factors. Multiple logistic regression analysis involving a backward elimination selection procedure
was used to select independent predictors. We compared positive rates regarding 6-core and 12-core biopsy
schemes at different risk levels. In the second stage of the study, 238 cases were evaluated using our nomogram.
In higher risk patients, we employed a 6 + 1 core biopsy. Positive rates in the first and second stages of the study
were compared.
Results: Age, the baseline median natural logarithm of PSA (Ln[PSA]), Ln(PV), f/t, rate of abnormal DRE findings
and rate of hypoechoic masses detected using TRUS were the factors that were finally submitted into our
nomogram. A significantly greater area under the receiver-operating characteristic curve was obtained for
the nomogram than for PSA level alone (0.853 vs. 0.761). A cancer probability cutoff value of 0.5 suggested
no significant difference between the 6-core and 12-core biopsy schemes at higher risk levels. In the second
stage of the study we verified that in patients with a cancer probability cutoff value >0.5, a 6 + 1-core biopsy
could be used without a reduction in the positive detection rate, and significantly reducing the number of biopsy
cores required.
Conclusions: A nomogram based on data from Chinese males was developed to predict the positive
detection rate, ratio of positive cores and Gleason score at each risk level. According to this nomogram, a
reasonable biopsy strategy could be constituted to reduce the number of biopsy cores required in subjects at
high risk.
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Background
Nowadays, prostate-specific antigen (PSA) is the most
widely used biomarker for prostate cancer diagnosis.
Nevertheless, the specificity of PSA in predicting prostate
cancer is not satisfactory [1]. Some evolutional indexes,
such as PSA velocity, PSA density (PSAD) and free/total
PSA ratio (f/t), are used clinically; however, they are all
provincial because of their dependence on PSA [2,3]. No-
mograms, which are based on multiple independent risk
factors for prostate cancer, have shown their superiority in
detecting this cancer [4]. Although there are two well-
known nomograms that have been used for incorporating
known risk factors, namely in the Prostate Cancer Preven-
tion Trial (PCPT) and in the European Randomized Study
of Screening for Prostate Cancer (ERSPC), previous re-
search has shown that they may not be directly applicable
to Chinese males [5-7]. Therefore, it is necessary to de-
velop a new prostate cancer risk assessment nomogram
designed for the Chinese population.
The trans-rectal ultrasound (TRUS)-guided sextant bi-
opsy method has been considered a standard method
for obtaining prostatic tissues for histological evaluation
since it was introduced by Hodge et al. [8] in 1989. Since
then, surgeons have used additional cores to improve the
accuracy of detection of prostate cancer [9-14]. Obviously,
the extraction of additional cores can lead to excessive
harm to the patient. According to our biopsy experience,
as a result of the lack of PSA screening in most regions of
China, a large number of positive cases of prostate cancer
involving more than six positive cores have been diag-
nosed. In the present study, with the help of our nomo-
gram we have attempted to identify cases in which we
could reduce the number of biopsy cores required.
Methods
Ethics statement
This study was approved by the institutional review
board of the First Affiliated Hospital of Nanjing Medical
University. Written informed consent was obtained from
all patients with regard to the storage of their information
for the purpose of research. All research procedures were
conducted in accordance with the Declaration of Helsinki.
First stage
The first stage of this study included 1104 patients
who had undergone a TRUS-guided prostate biopsy
from July 2009 to September 2012 at the First Affiliated
Hospital of Nanjing Medical University, China. A pro-
portion of the patients had elevated PSA levels or ab-
normal digital rectal examination (DRE) findings during
routine physical examination; the remaining patients had
lower urinary tract symptoms with elevated PSA. Detailed
patient information, including age, PSA, free (f)PSA and
DRE findings, was recorded before biopsy. Every patient
underwent calculation of prostate volume (PV) using an el-
lipsoid formula (PI/6*lateral*anteroposterior*superoinferior
diameters) by means of ultrasonoscopy, and detailed obser-
vations were carried out regarding hypoechoic lesions
and microcalcifications. PSAD was defined as the ratio of
PSA to PV. The percentage of fPSA (the free/total PSA
ratio [f/t]) was calculated by dividing the level of fPSA
present by the total level of PSA.
The biopsy scheme included 13 cores; six mid cores
were performed as a traditional 6-core biopsy, another
six cores were performed parallel and lateral to the six mid
cores, and the final core was directed at a hypoechoic le-
sion under ultrasound or performed at the apex of the
prostate. The locations of positive cores were recorded in
detail. We supposed that every patient received two biopsy
schemes, namely systemic 12-core and traditional 6-core.
After analysis of the locations of positive cores, the results
from 6-core and 12-core biopsy were recorded.
Multiple logistic regression analysis with a backward
elimination selection procedure was used to select inde-
pendent predictors of prostate cancer in the model-
building set. An equation for prostate cancer probability
(PCP) was developed based on the final logistic regres-
sion model. On the basis of the value obtained from the
PCP equation, we classified risk into five levels and eval-
uated the rate of positives, the Gleason score and the
average number of positive cores at every risk level. Fur-
thermore, we compared the differences in the positive
rate between 6-core and 12-core biopsies at the various
Table 1 Characteristics of the patient cohort in the first
stage of the study
Variables POS* NEG* P
N (%) N (%)
Number of patients 458 (41.49) 646 (58.51)
Age 70.8 ± 6.9 67.4 ± 8.4 <0.001
PSA 120.4 ± 15.0 13.7 ± 18.0 <0.001
PV 41.2 ± 24.4 48.2 ± 27.6 <0.001
PSAD 2.9 ± 13.5 0.3 ± 0.4 <0.001
f/t 0.12 ± 0.07 0.16 ± 0.10 <0.001
DRE findings <0.001
neg* 234 (28.6) 585 (71.4)
pos* 224 (78.6) 61 (21.4)
Hypoechoic# <0.001
neg* 307 (37.2) 518 (62.8)
pos* 151 (54.1) 128 (45.9)
Microcalcification# 0.592
neg* 319 (40.9) 460 (59.1)
pos* 139 (42.8) 186 (57.2)
*neg, negative; *pos, positive.
#Hypoechoic masses and microcalcifications were observed using ultrasound.
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levels of risk and determined a rational biopsy strategy.
With the help of our model, we found a PCP cutoff
value to identify the patients in which there was no
significant difference in the rate of positives between
6-core and 12-core biopsies. In these patients 6 + 1-core
biopsy was considered more reasonable than 12 + 1-core
biopsy.
Second stage
In the second stage of the study, we prospectively inves-
tigated whether or not a reduction in the number of bi-
opsy cores in high-risk patients would lead to a decrease
in the rate of positive cases. A total of 238 patients were
evaluated using our model and patients at high risk were
recommended for the 6 + 1 biopsy scheme. We com-
pared the positive core rate and the number of cores
taken in the first and second stages of the study.
Statistical analysis
Statistical analysis was performed using SPSS 18.0 soft-
ware. Differences between data sets were analyzed using
the t-test. Data were expressed as the mean ± standard
deviation. The Chi-square test was used to compare cat-
egorical variables. A P value < 0.05 was considered as be-
ing statistically significant.
Results
Among 1104 consecutive patients in the first stage of the
study, 458 (41.49%) had positive biopsy results. Patient
characteristics are detailed in Table 1. The mean ages of
patients in the cancer and non-cancer groups in our study
cohort were 70.8 ± 6.9 years and 67.4 ± 8.4 years, respect-
ively (P < 0.001). The PSA level (P < 0.001), PV (P < 0.001),
PSAD (P < 0.001), f/t (P < 0.001), and the rates of abnormal
DRE (P < 0.001) findings and hypoechoic masses detected
using TRUS (P < 0.001) differed significantly between the
cancer and the non-cancer groups (Table 2). Because the
PSA level and the PV had a non-normal distribution, these
variables were transformed to the natural logarithm before
univariate analysis. Univariate analysis indicated that age,
Ln(PSA), Ln(PV), f/t, the rate of abnormal DRE and the
rate of hypoechoic lesions on TRUS in patients with a posi-
tive initial biopsy were all significantly different from
patients with a negative biopsy.
Variables used to build the nomogram were selected
using a backward elimination scheme; only age, Ln(PSA),
Ln(PV), f/t, abnormal DRE and hypoechoic lesions
on TRUS were chosen for inclusion in our nomogram
(Figure 1). The equation for prostate cancer probability
(PCP) was derived using the logistic regression model:
Table 2 Multivariate analysis of the predictors of
prostate cancer
Variables OR 95% CI P
Age 1.056 1.034 1.078 <0.001
Ln(PSA) 2.218 1.552 3.169 <0.001
Ln(PV) 0.311 0.2 0.483 <0.001
PSAD 1.322 0.791 2.207 0.287
f/t 0.021 0.002 0.187 0.001
DRE findings* 5.276 3.578 7.78 <0.001
Hypoechoic* 1.562 1.095 2.229 0.014
Microcalcification* 1.045 0.748 1.46 0.799
*Reference category was negative.
Figure 1 Nomogram for predicting a positive rate. Locate patient values on each axis, and compare to the ‘Point’ axis to determine how
many points are attributed to each variable. Then locate the sum of the points for all variables on the ‘Total Points’ line to determine the
individual probability of prostate cancer on the ‘risk of PCa’ line.
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The PCP equation was developed to calculate patient
risk level regarding the Cacoethic biopsy results. The area
under the curve (AUC) of the receiver-operating character-
istic curve for the nomogram is shown in Figure 2A. The
AUC was increased from 0.761 for PSA alone to 0.853 for
our nomogram.
In accordance with the value obtained from the PCP
equation, we classified the probability of prostate cancer
occurrence into five levels, and the cutoffs were at 0.2,
0.4, 0.6 and 0.8, as each demarcation point declined to a
lower level. The rate of positive prostate biopsies in-
creased in line with the risk level (Figure 2B).
In patients with positive biopsy results, the number of
positive cores counted and the percentage of low Gleason
scores (<7) for every risk level are shown in Figures 2C
and D, respectively. Coupled with increasing risk level, the
PCP ¼ e
‐3:577þ0:054 Ageð Þ ‐3:714 f=tð Þ ‐1:324 Ln PVð Þð Þ þ 0:977 Ln PSAð Þð Þ þ1:698 DRE findingsð Þ þ0:458 hypoechoicð Þ
1þ e‐3:577þ0:54 Ageð Þ ‐3:714 f=tð Þ ‐1:324 Ln PVð Þð Þ þ Ln PSAð Þð Þþ 1:698 DRE findingsð Þ þ 0:458 hypoechoicð Þ :
Figure 2 The ROC of our nomogram and predictive information in every risk degree. (A) The solid line represents the receiver-operating
characteristic curve for the nomogram. (B) The strips represent the positive rate in patients at every risk level. (C) The strips represent the average
number of positive cores taken from patients with positive results at every risk level. (D) The line represents the number of patients with positive
results and a lower Gleason score (<7).
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proportion of patients with lower Gleason scores decreased
and there was a distinct increase in the mean number of
positive cores.
Retrospective analysis of 1104 cases indicated that only
a proportion of malignancies could be detected using
12-core rather than 6-core biopsy. When the PCP cutoff
value reached 0.5 there was no significant difference
in the detection rate between 6-core and 12-core biopsy
in patients with higher PCP values (72.9% vs. 78.6%;
P = 0.077); however, the difference in the detection rate
in patients with lower PCP values was still significant
(14.6% vs. 20.4%; P = 0.004). In patients with a PCP >0.5,
6 + 1 core biopsy was found to be more reasonable than
12 + 1-core biopsy.
From November 2012 to June 2013, a total of 238
patients were evaluated using our new nomogram;
patients with a PCP cutoff value >0.5 were recommended
for 6 + 1-core biopsy. The remaining patients still received
systemic 12 + 1-core biopsy. The additional core was only
performed in patients with hypoechoic lesions detected
using TRUS. We found that 78 patients had a PCP cut-
off value >0.5; 71 of these patients agreed to undergo
a simplified biopsy scheme (6 + 1-core) and the other
seven patients insisted on biopsy using the old scheme
(12 + 1-core). Table 3 shows the comparison of data re-
garding the first and second stages of the study. In the
second stage, we significantly reduced the number of bi-
opsy cores (6.9 ± 2.1 vs. 13; P < 0.001) in patients with a
PCP cutoff level >0.5; however, there was no significant dif-
ference in the detection rate (70.5% vs. 78.6%; P = 0.109).
Discussion
Measurement of the level of PSA in serum in the elderly
can help clinicians to diagnose prostate cancer at an
early stage. However, other medical conditions, such as
benign prostatic hypertrophy and inflammation, can ele-
vate the PSA level in serum [14]. Because of the low
specificity of the PSA level in the detection of prostate
cancer, patients suspected of having this disease using
PSA screening usually receive an unnecessary biopsy;
this is an invasive procedure with accompanying compli-
cations [15]. The benefit of PSA screening in prolonging
cancer-specific survival remains controversial [16,17].
Previous research has shown that predictive models,
based on clinical, laboratory and ultrasound parame-
ters can improve the accuracy of prostate cancer detec-
tion to varying degrees [18-20]. In the present study, Ln
(PV), f/t, age, Ln(PSA), the rate of abnormal DRE find-
ings and the rate of hypoechoic masses detected using
TRUS have been taken into account for the first time.
The equation used in the calculation of the PCP was de-
rived for the diagnosis of prostate cancer. In contrast to
PSA alone, use of our nomogram enlarged the AUC from
0.761 to 0.853. As shown in Figure 2B, C and D, we could
evaluate the positive core rate, Gleason score and esti-
mate the number of positive cores. In principle, a higher
risk level means a higher positive rate, a higher Gleason
score and more calculations regarding positive cores. As
is evident in Figure 2C, the general tendency regarding
the mean number of positive cores is not adequate in the
first risk level; however, the difference between the first
risk level and the second risk level was not significant
(4.32 vs. 3.84; P = 0.473).
More recently, surgeons have used additional biopsy
cores to improve the accuracy of detection of prostate
cancer [9-14]. However, it has been reported in some
studies that there is no significant difference between
6-core biopsy and 12-core biopsy in terms of the rate of
positive biopsy cores [21,22]. According to our nomo-
gram, when the cancer probability cutoff value reached
0.5 there was no significant difference between 6-core
biopsy and 12-core biopsy at higher risk levels; however,
the difference between 6-core and 12-core biopsy at
lower risk levels was significant. The tumor volume ratio
of the prostate may explain this. This ratio is smaller at
lower risk levels, requiring the use of concentrated bi-
opsy cores. In patients diagnosed with malignancy, the
positive rate regarding the 13th core biopsy of hypoe-
choic masses detected using ultrasound was signifi-
cantly higher than any biopsy core obtained using systemic
12-core biopsy (70.9% vs. 56.6%; P < 0.001). In summary,
taking the threshold value as being a cutoff value of 0.5,
Table 3 Comparison of the new and old biopsy schemes




Age 69.7 ± 7.3 68.8 ± 7.9 0.116
Biopsy cores 10.5 ± 2.8 13 <0.001
Positive rate 85(35.7) 458(41.5) 0.109
Subjects with PCP > 0.5
N 78 384
Age 72.2 ± 6.8 71.7 ± 6.9 0.51
Biopsy cores 6.9 ± 2.1 13 <0.001
Positive rate 55(70.5) 302(78.6) 0.138












535 44.8 0.848 0.797 0.051
Our model 1104 41.5 0.853 0.761 0.092
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6-core biopsy was found to be adequate for patients at
higher risk levels (cutoff >0.5), and 12-core biopsy was
found to be adequate for the other patients. If there are
hypoechoic lesions on ultrasound, performing an extra
core biopsy would be helpful. This new biopsy scheme
was found to reduce the number of biopsies required
and did not decrease the positive core rate in the second
stage of our study.
Unfortunately, our nomogram is not the first to have
been developed in China. But our nomogram was based
on twice the number of patients used in former nomo-
grams involving Chinese populations (Table 4); this
may have led to more reliable results. Furthermore, our
nomogram has greater clinical applicability. We could
roughly predict the positive core rate, ratio of positive
cores and Gleason score at every risk level. Finally, with
the help of our nomogram, we identified those high-risk
patients in which we could reduce the number of biopsy
cores by half.
Conclusions
A nomogram based on data from Chinese males was de-
veloped to predict the positive core rate, ratio of positive
cores and Gleason score at the various high-risk levels.
A reasonable biopsy strategy based on our new nomo-
gram was demonstrated to reduce the number of biopsy
cores required in high-risk patients.
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